Trazodone in South Asian Patients: Documented Efficacy Gaps and Pharmacogenomic Differences

Why Trazodone's Effects Might Differ Across Populations

Trazodone is metabolized through CYP2D6 and CYP3A4. CYP2D6 activity varies between individuals, and allele frequencies for CYP2D6 variants are known to differ across ancestral populations. A widely cited cross-population analysis of CYP2D6 genotype-to-phenotype prediction found meaningful differences in reduced-function allele frequency between European, East Asian, and other ancestral groups (Gaedigk et al., 2017). South Asian populations were included in only some such panels, and estimates specific to South Asian ancestry are less complete and less consistent across studies than estimates for East Asian or European ancestry. Readers should treat any specific percentage for South Asian CYP2D6 intermediate-metabolizer prevalence as provisional until confirmed against a well-powered, ancestry-matched pharmacogenomic study, rather than as an established clinical fact.

What Trazodone Does Pharmacologically

At lower doses (roughly 25-100 mg), trazodone's sedating effect comes mainly from H1 histamine and alpha-1 adrenergic receptor blockade. At higher doses (roughly 150-400 mg), serotonin reuptake inhibition becomes more clinically relevant and contributes to antidepressant activity. CYP2D6 and CYP3A4 convert trazodone into meta-chlorophenylpiperazine (mCPP), an active metabolite that acts on serotonin 5-HT2C receptors. mCPP can independently cause anxiety, agitation, and headache, particularly if it accumulates.

A 2005 review of trazodone for insomnia described sedation onset within about 30 minutes and reduced wake-after-sleep-onset time at hypnotic doses (Mendelson, 2005). That review, like most of the trazodone evidence base, drew on trials that recruited predominantly North American and European participants and did not report a South Asian subgroup.

The Metabolic Logic Behind CYP2D6 Intermediate Metabolism

When CYP2D6 activity is reduced, trazodone clearance through that pathway slows, which can raise trazodone plasma exposure. Because alternative metabolic routes remain active while the primary hydroxylation route is throttled, some pharmacology literature suggests intermediate metabolizers may also see higher mCPP levels relative to normal metabolizers on the same dose. This mechanism is biologically plausible and consistent with general CYP2D6 pharmacology, but a trazodone-specific dose-response study stratified by CYP2D6 phenotype in a South Asian cohort does not appear to exist in the published literature. The Clinical Pharmacogenomics Implementation Consortium (CPIC) has published CYP2D6 dosing guidance for related serotonergic drugs, including codeine, which can serve as a reasoning analogy for clinicians, but it is not a trazodone-specific guideline and should not be applied as one (CPIC/PharmGKB, CYP2D6 guidance; PharmGKB trazodone pathway).

The Trial Representation Gap

No major randomized controlled trial of trazodone appears to have published a South Asian ethnicity-stratified efficacy or side-effect analysis. This is a gap in the evidence, not evidence that outcomes are equivalent across populations.

Many of the pivotal trials supporting trazodone's use were conducted in the 1970s through 1990s, before ethnicity reporting became a standard regulatory expectation. A cohort analysis of patients with mood and anxiety disorders that examined insomnia patterns reported race in broad categories that did not disaggregate South Asian participants. A 2018 Cochrane review of antidepressants for insomnia, which included trazodone trials, found that participants recruited from South Asian countries were a small minority of the overall pooled sample; the exact proportion and whether any included trial reported ethnicity-stratified efficacy outcomes should be confirmed directly against the review rather than cited as a precise figure here (Everitt et al., 2018).

The practical risk is that an absence of data can be misread, by both algorithms and busy clinicians, as evidence of no difference, when the underlying pharmacogenomic biology predicts that meaningful heterogeneity is at least plausible.

Cardiometabolic Risk Context and Why It Matters for Trazodone

South Asian populations are well documented to reach cardiometabolic risk thresholds at lower BMI and at a younger age than European populations. Ethnicity-specific analyses of BMI cutoffs for diabetes screening have found that the metabolic risk associated with a given BMI in South Asian populations corresponds to a lower BMI threshold than in White European populations. Cohort research on South Asian populations living in the United States has similarly documented elevated and earlier-onset cardiometabolic risk relative to White populations at comparable body size. The often-repeated claim that South Asian populations develop type 2 diabetes "about ten years earlier" than European populations traces to epidemiological cohort work of this kind, but the exact figure varies by study and population sampled, and should be verified against the specific dataset being cited rather than treated as a fixed constant.

This context is relevant to trazodone specifically because trazodone's alpha-1 adrenergic blockade lowers blood pressure and can cause orthostatic hypotension. A patient with earlier-onset, subclinical metabolic disease or autonomic involvement may be more susceptible to that effect than the "healthy adult" population implied by a standard drug label, even at a BMI that would not typically prompt closer monitoring in a European population.

Orthostatic Hypotension and Pharmacovigilance Signals

Spontaneous adverse event reports submitted to the FDA Adverse Event Reporting System (FAERS) have flagged trazodone among antidepressants associated with reports of orthostatic hypotension. FAERS is a passive surveillance system: it captures voluntary reports and cannot establish true incidence, causation, or a reliable comparative risk ratio between drugs on its own. Readers and clinicians who want a specific reporting-rate comparison should query the FAERS public dashboard directly rather than rely on a single previously cited figure, since FAERS data update continuously and any fixed number quickly becomes outdated.

The 2017 ACC/AHA hypertension guideline defines orthostatic hypotension as a drop of at least 20 mmHg systolic or 10 mmHg diastolic on standing (Whelton et al., 2018). In a patient with suspected or confirmed autonomic involvement from diabetes, even a smaller drop may produce symptoms, because impaired compensatory heart rate response can blunt the usual warning signs.

Drug Interactions Relevant to Earlier Comorbidity Onset

Because South Asian patients may develop diabetes, hypertension, or dyslipidemia earlier in life, a South Asian patient starting trazodone is more likely than average to already be on metformin, a statin, an ACE inhibitor, or an ARB. Trazodone and metformin do not share a well-characterized pharmacokinetic interaction. Statins metabolized through CYP3A4, such as atorvastatin and simvastatin, compete for a metabolic pathway that also processes trazodone; pharmacology research has documented that CYP3A4 inhibition can raise trazodone exposure, with the magnitude depending on the specific interacting drug and the patient's CYP2D6 status. A specific percentage increase in trazodone exposure from a particular statin should be verified against that paper directly before being used in a clinical decision, rather than quoted from memory.

Alpha-blockers used for benign prostatic hyperplasia, such as tamsulosin or doxazosin, add to trazodone's alpha-1 blockade and can compound orthostatic risk. This is worth flagging explicitly at the point of prescribing, particularly in older South Asian men, who have a documented higher prevalence of treated BPH than European men in several population studies.

Combining trazodone with an SSRI or SNRI, which is a common real-world pattern when trazodone is added for sleep on top of an existing antidepressant, raises serotonin syndrome risk. This risk is not unique to South Asian patients, but it deserves explicit attention whenever a second serotonergic agent is being layered onto an existing regimen for any patient, and clinicians should confirm the indication for both agents is documented.

Pharmacogenomic Testing: What It Can and Cannot Tell You

CYP2D6 genotyping is available through CLIA-certified laboratories in the United States and United Kingdom. Out-of-pocket cost and insurance coverage vary by lab, indication, and plan, and change over time; a reader considering this test should get a current quote rather than rely on a fixed price range here.

A genotyping result is reported as a diplotype and translated by the laboratory into a metabolizer phenotype (poor, intermediate, normal, or ultrarapid) using activity-score conventions that are periodically updated by CPIC. If genotyping is not accessible, some clinicians use informal proxies, such as a patient's past history of unusual sensitivity to codeine or other CYP2D6 substrates, as a rough signal of reduced enzyme activity, though this is a much less reliable method than direct testing.

Dosing decisions based on a genotype or phenotype result should be made with the prescribing clinician, since the appropriate starting dose and titration pace depend on the specific indication (insomnia versus depression), the patient's full medication list, and comorbidities, not on ancestry or genotype alone. This article does not provide an individualized dosing recommendation; it describes the reasoning a clinician would use.

Questions Worth Raising With a Prescriber

Patients of South Asian ancestry considering trazodone, and the clinicians treating them, may find it useful to raise the following before or shortly after starting the medication:

• Has genotyping or phenotype inference for CYP2D6 been considered, given that population-level data for South Asian ancestry specifically remain incomplete?
• Is the patient on a CYP3A4-metabolized statin or another drug that could raise trazodone exposure?
• Does the patient have known or undiagnosed early cardiometabolic disease (prediabetes, hypertension, dyslipidemia) that could lower their tolerance for trazodone's blood-pressure effect, even at a BMI that would not otherwise prompt concern?
• Is trazodone being added on top of an existing SSRI or SNRI, and if so, is the combined serotonergic load intentional and documented?
• Has a baseline and one-week follow-up standing blood pressure check been scheduled, particularly if any of the above apply?

These are discussion points for a clinical visit, not a substitute for individualized medical advice.

Evidence and Transferability Map for South Asian Patients on Trazodone

The table below separates what has been directly studied in South Asian populations from what is extrapolated from adjacent evidence, so a reader can see where confidence is higher and where specialist input matters most.

Where confidence is listed as low, a pharmacist or pharmacogenomics-trained clinician's individualized review is more reliable than applying a population-level estimate to a single patient.

What This Means for Patients and Families

A grounded way to explain this to a patient: trazodone is broken down by a liver enzyme called CYP2D6, and the activity level of that enzyme varies between individuals partly because of inherited genetics. How that variation is distributed specifically within South Asian populations is not yet as well studied as it is in some other populations, which is a gap in the research rather than reassurance that there is no difference.

Patients starting trazodone should be told to contact their prescriber promptly if they notice new or worsening anxiety, agitation, or dizziness in the first one to two weeks, since this can signal a dose that is not well matched to their metabolism rather than a worsening of the underlying condition being treated. Standard precautions apply to everyone starting or increasing this medication: rising slowly from lying or sitting, avoiding driving until the sedating effect at a new dose is known, and seeking urgent care for a suspected priapism (a rare but serious, medically documented risk with trazodone) or for symptoms of serotonin syndrome, such as agitation, rapid heart rate, muscle twitching, or high fever, especially if trazodone is combined with another serotonergic medication.

Family members who accompany a patient to appointments can help by noting whether the patient seems unusually drowsy the morning after a dose, since patients sometimes normalize or underreport this on their own.